Bristol-Myers Squibb Co (BMY)
27 Oct 2016
NEW YORK, Oct 27 The long, dark tunnel that has been the U.S. presidential election campaign for biotechnology stocks appears to have no bright light beckoning the sector's beleaguered shareholders to a welcoming end.
Oct 27 Bristol-Myers Squibb Co, whose high-profile Opdivo immunotherapy failed an important lung-cancer trial last summer, sharply raised its 2016 profit forecast after strong quarterly sales of other leading medicines.
Bristol-Myers Squibb Co , whose high-profile Opdivo immunotherapy failed an important lung-cancer trial last summer, sharply raised its 2016 profit forecast after strong quarterly sales of other leading medicines.
* Bristol-Myers squibb reports third quarter financial results
Oct 27 Bristol-Myers Squibb Co sharply raised its 2016 profit forecast after surprisingly strong quarterly sales for a handful of its other leading prescription drugs.
* New results presented for opdivo (nivolumab) demonstrate encouraging response rate in an expanded population of heavily pre-treated classical hodgkin lymphoma patients
Merck & Co has won U.S. approval to market its immunotherapy Keytruda for use in previously untreated lung cancer patients two months ahead of schedule, making it the only such drug cleared for first-line treatment.
* FDA moves cement Merck's leading position in lung cancer (Adds more detail on approval, competition, analyst comment)
ZURICH Roche said on Thursday strong sales of new medicines like cancer immunotherapy drug Tecentriq would help to sustain the company's growth as patents on older drugs start to expire.
* Keeps full-year outlook (Adds CEO, analyst comment, updates shares)
|Johnson & Johnson (JNJ.N)||$115.70||+1.14|
|Pfizer Inc. (PFE.N)||$32.48||+0.08|
|Merck & Co., Inc. (MRK.N)||$61.29||+0.42|
|Sanofi SA (SASY.PA)||€68.86||+0.75|
|AstraZeneca plc (AZN.L)||4,614.50p||-162.50|
|GlaxoSmithKline plc (GSK.L)||1,630.50p||+4.00|
|Eli Lilly and Co (LLY.N)||$76.16||-0.60|
|Roche Holding Ltd. (ROG.S)||CHF230.30||+3.80|
|Roche Holding Ltd. (RO.S)||CHF233.90||+4.40|